Drugs / Eravacycline
Eravacycline
also known as
TP-434 · Eravaciclina · ERAVACYCLINE DIHYDROCHLORIDE · TP-434-046 · Trade name: Xerava · Xerava
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Xerava | — | 2018-09-20 | europa.eu ↗ |
| Approved | US (FDA) | XERAVA | — | 2018-08-27 | fda.gov ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03696550 | Dec 2018 → Mar 2021 | bacterial infectious disease | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02135276 | Dec 2013 → Mar 2014 | end stage renal failure | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02135302 | Oct 2013 → Feb 2014 | — | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01941446 | Mar → Jun 2013 | — | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01989949 | Nov 2012 → Jan 2013 | — | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06794541 | May 2025 → Feb 2029 expected | — | Tetraphase Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT05537896 | Feb 2024 → Feb 2028 expected | hematopoietic and lymphoid cell neoplasm, neutropenia | West Virginia University | Recruiting | No outcome recorded |
| Phase 2 | NCT01265784 | Jan 2011 → May 2012 | — | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03032510 | Jan → Dec 2017 | urinary tract infection | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02784704 | Oct 2016 → May 2017 | appendicitis | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01978938 | Oct 2014 → Jun 2015 | urinary tract infection | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01844856 | Aug 2013 → Aug 2014 | — | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07004049 Comparator | Apr 2025 → Dec 2028 expected | bacterial pneumonia, infectious disease with sepsis | National University of Singapore | Recruiting | No outcome recorded |
| Phase 4 | NCT06440304 Comparator | Jan 2025 → Dec 2026 expected | bacterial infectious disease with sepsis | Clinical Hospital Centre Zagreb | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eravacycline | “A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization” NCT01941446 ↗12“TP-434 (Eravacycline) reconstituted and administered via an IV infusion” NCT01989949 ↗ |
| Known as | Eravaciclina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1951095 ↗ |
| Known as | ERAVACYCLINE DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1951095 ↗ |
| Known as | TP-434 | “A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization” NCT01941446 ↗ |
| Known as | TP-434-046 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1951095 ↗ |
| Known as | Trade name: Xerava | “Trade name: Xerava™” NCT03696550 ↗ |
| Known as | Xerava | ChEMBL registry synonym — accepted as the source's own label CHEMBL1951095 ↗ |
| Modality | Small molecule | “Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class” PMID 27851857 ↗ Mar 2017 |
| Route | Intravenous | “TP-434 was administered intravenously (IV)” NCT01265784 ↗ |